{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:51:22Z","timestamp":1787003482918,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lymphoma is the most common hematological cancer in dogs. Canine diffuse large B cell lymphoma shows a relatively good response to treatment with multi-agent cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy; however, the 2-year survival rate is as low as 20%. For human B cell type lymphoma, the anti-CD20 chimeric antibody, rituximab, was developed two decades ago. The combination of rituximab and CHOP chemotherapy was highly successful in improving patient prognosis. However, no anti-canine CD20 antibody is available for the treatment of canine lymphoma. During this study, a rat anti-canine CD20 monoclonal antibody was established. We also generated a rat-canine chimeric antibody against canine CD20 designed for clinical application. This chimeric antibody (4E1-7-B) showed in vitro antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against the canine B cell lymphoma cell line CLBL-1. Moreover, to obtain stronger ADCC activity, a defucosylated 4E1-7-B antibody (4E1-7-B_f) was also generated, and it showed tenfold stronger ADCC activity compared with 4E1-7-B. 4E1-7-B_f as well as 4E1-7-B suppressed the growth of CLBL-1 tumors in an immunodeficient xenotransplant mouse model. Finally, a single administration of 4E1-7-B_f induced considerable peripheral B cell depletion in healthy beagles. Thus, 4E1-7-B_f is a good antibody drug candidate for canine B cell type lymphoma.<\/jats:p>","DOI":"10.1038\/s41598-020-68470-9","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T06:04:06Z","timestamp":1594361046000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment"],"prefix":"10.1038","volume":"10","author":[{"given":"Takuya","family":"Mizuno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5385-8201","authenticated-orcid":false,"given":"Yukinari","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4158-9208","authenticated-orcid":false,"given":"Mika K.","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinori","family":"Shiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Tsukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Takemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Tokimasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Nemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Igase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,10]]},"reference":[{"key":"68470_CR1","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.vetimm.2014.02.016","volume":"159","author":"D Ito","year":"2014","unstructured":"Ito, D., Frantz, A. M. & Modiano, J. F. Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications. Vet. Immunol. Immunopathol. 159, 192\u2013201 (2014).","journal-title":"Vet. Immunol. Immunopathol."},{"key":"68470_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fvets.2016.00077","volume":"3","author":"L Aresu","year":"2016","unstructured":"Aresu, L. Canine lymphoma, more than a morphological diagnosis: what we have learned about diffuse large B-cell lymphoma. Front Vet Sci. 3, 77. https:\/\/doi.org\/10.3389\/fvets.2016.00077 (2016).","journal-title":"Front Vet Sci."},{"key":"68470_CR3","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.cvsm.2019.04.004","volume":"49","author":"DH Thamm","year":"2019","unstructured":"Thamm, D. H. Novel treatments for lymphoma. Vet. Clin. North Am. Small Anim. Pract. 49, 903\u2013915 (2019).","journal-title":"Vet. Clin. North Am. Small Anim. Pract."},{"key":"68470_CR4","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","volume":"83","author":"ME Reff","year":"1994","unstructured":"Reff, M. E. et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83, 435\u2013445 (1994).","journal-title":"Blood"},{"key":"68470_CR5","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1016\/j.molimm.2007.06.151","volume":"44","author":"MJ Glennie","year":"2007","unstructured":"Glennie, M. J., French, R. R., Cragg, M. S. & Taylor, R. P. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 44, 3823\u20133837 (2007).","journal-title":"Mol. Immunol."},{"key":"68470_CR6","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","volume":"34","author":"G Salles","year":"2017","unstructured":"Salles, G. et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv. Ther. 34, 2232\u20132273 (2017).","journal-title":"Adv. Ther."},{"key":"68470_CR7","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1182\/asheducation-2007.1.233","volume":"2007","author":"C Bello","year":"2007","unstructured":"Bello, C. & Sotomayor, E. M. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematol. Am. Soc. Hematol. Educ. Program. 2007, 233\u2013242 (2007).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"68470_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11912-018-0748-0","volume":"20","author":"CL Freeman","year":"2018","unstructured":"Freeman, C. L. & Sehn, L. Anti-CD20 directed therapy of b cell lymphomas: are new agents really better?. Curr. Oncol. Rep. 20, 103 (2018).","journal-title":"Curr. Oncol. Rep."},{"key":"68470_CR9","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.1182\/blood-2013-05-504043","volume":"122","author":"J Golay","year":"2013","unstructured":"Golay, J. et al. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood 122, 3482\u20133491 (2013).","journal-title":"Blood"},{"key":"68470_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1158\/2326-6066.CIR-14-0125","volume":"3","author":"SD Liu","year":"2015","unstructured":"Liu, S. D. et al. Afucosylated antibodies increase activation of Fc\u03b3RIIIa-dependent signaling components to intensify processes promoting ADCC. Cancer Immunol. Res. 3, 173\u2013183 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"68470_CR11","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-09-2697","volume":"16","author":"T Ishii","year":"2010","unstructured":"Ishii, T. et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia\/lymphoma. Clin. Cancer Res. 16, 1520\u20131531 (2010).","journal-title":"Clin. Cancer Res."},{"key":"68470_CR12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00281-014-0427-7","volume":"36","author":"D Kao","year":"2014","unstructured":"Kao, D., Lux, A., Schwab, I. & Nimmerjahn, F. Targeting B cells and autoantibodies in the therapy of autoimmune diseases. Semin. Immunopathol. 36, 289\u2013299 (2014).","journal-title":"Semin. Immunopathol."},{"key":"68470_CR13","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1354\/vp.42-4-468","volume":"42","author":"CM Jubala","year":"2005","unstructured":"Jubala, C. M. et al. CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma. Vet. Pathol. 42, 468\u2013476 (2005).","journal-title":"Vet. Pathol."},{"key":"68470_CR14","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.tvjl.2005.03.005","volume":"171","author":"JA Impellizeri","year":"2006","unstructured":"Impellizeri, J. A., Howell, K., McKeever, K. P. & Crow, S. E. The role of rituximab in the treatment of canine lymphoma: an ex vivo evaluation. Vet. J. 171, 556\u2013558 (2006).","journal-title":"Vet. J."},{"key":"68470_CR15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3109\/10428194.2014.914193","volume":"56","author":"D Ito","year":"2015","unstructured":"Ito, D., Brewer, S., Modiano, J. F. & Beall, M. J. Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential. Leuk Lymphoma 56, 219\u2013225 (2015).","journal-title":"Leuk Lymphoma"},{"key":"68470_CR16","doi-asserted-by":"publisher","first-page":"e0148366","DOI":"10.1371\/journal.pone.0148366","volume":"11","author":"S Jain","year":"2016","unstructured":"Jain, S. et al. The development of a recombinant scFv monoclonal antibody targeting canine CD20 for use in comparative medicine. PLoS ONE 11, e0148366. https:\/\/doi.org\/10.1371\/journal.pone.0148366 (2016).","journal-title":"PLoS ONE"},{"key":"68470_CR17","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.vetimm.2015.02.004","volume":"164","author":"SM Rue","year":"2015","unstructured":"Rue, S. M. et al. Identification of a candidate therapeutic antibody for treatment of canine B-cell lymphoma. Vet. Immunol. Immunopathol. 164, 148\u2013159 (2015).","journal-title":"Vet. Immunol. Immunopathol."},{"key":"68470_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0165-2427(01)00318-X","volume":"80","author":"L Tang","year":"2001","unstructured":"Tang, L., Sampson, C., Dreitz, M. J. & McCall, C. Cloning and characterization of cDNAs encoding four different canine immunoglobulin gamma chains. Vet. Immunol. Immunopathol. 80, 259\u2013270 (2001).","journal-title":"Vet. Immunol. Immunopathol."},{"key":"68470_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.vetimm.2013.10.018","volume":"157","author":"LM Bergeron","year":"2014","unstructured":"Bergeron, L. M. et al. Comparative functional characterization of canine IgG subclasses. Vet. Immunol. Immunopathol. 157, 31\u201341 (2014).","journal-title":"Vet. Immunol. Immunopathol."},{"key":"68470_CR20","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/bit.20151","volume":"87","author":"N Yamane-Ohnuki","year":"2004","unstructured":"Yamane-Ohnuki, N. et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol. Bioeng. 87, 614\u2013622 (2004).","journal-title":"Biotechnol. Bioeng."},{"key":"68470_CR21","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1089\/mab.2018.0035","volume":"37","author":"Y Kato","year":"2018","unstructured":"Kato, Y. et al. Establishment of P38Bf, a core-fucose-deficient mouse-canine chimeric antibody against dog podoplanin. Monoclon. Antib Immunodiagn. Immunother. 37, 218\u2013223 (2018).","journal-title":"Monoclon. Antib Immunodiagn. Immunother."},{"key":"68470_CR22","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1158\/2326-6066.CIR-16-0105","volume":"4","author":"K Weiskopf","year":"2016","unstructured":"Weiskopf, K. et al. Eradication of canine diffuse large B-cell lymphoma in a murine xenograft model with CD47 blockade and anti-CD20. Cancer Immunol. Res. 4, 1072\u20131087 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"68470_CR23","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0161-5890(92)90025-S","volume":"29","author":"K Mikl\u00f3s","year":"1992","unstructured":"Mikl\u00f3s, K., Tolnay, M., Bazin, H. & Medgyesi, G. A. Antibody mediated lysis of hapten-conjugated target cells by macrophages and by complement: the influence of IgG subclass, antibody and hapten density. Mol. Immunol. 29, 379\u2013384 (1992).","journal-title":"Mol. Immunol."},{"key":"68470_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1089\/mab.2017.0020","volume":"36","author":"MK Kaneko","year":"2017","unstructured":"Kaneko, M. K. et al. Antipodocalyxin antibody chPcMab-47 exerts antitumor activity in mouse xenograft models of colorectal adenocarcinomas. Monoclon. Antib. Immunodiagn. Immunother. 36, 157\u2013162 (2017).","journal-title":"Monoclon. Antib. Immunodiagn. Immunother."},{"key":"68470_CR25","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4049\/jimmunol.154.1.180","volume":"154","author":"LD Shultz","year":"1995","unstructured":"Shultz, L. D. et al. Multiple defects in innate and adaptive immunologic function in NOD\/LtSz-scid mice. J. Immunol. 154, 180\u2013191 (1995).","journal-title":"J. Immunol."},{"key":"68470_CR26","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.leukres.2010.01.021","volume":"34","author":"BC R\u00fctgen","year":"2010","unstructured":"R\u00fctgen, B. C. et al. Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma. Leuk Res. 34, 932\u2013938 (2010).","journal-title":"Leuk Res."},{"key":"68470_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/BF00205629","volume":"24","author":"Z Steplewski","year":"1987","unstructured":"Steplewski, Z., Jeglum, K. A., Rosales, C. & Weintraub, N. Canine lymphoma-associated antigens defined by murine monoclonal antibodies. Cancer Immunol. Immunother. 24, 197\u2013201 (1987).","journal-title":"Cancer Immunol. Immunother."},{"key":"68470_CR28","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1292\/jvms.58.469","volume":"58","author":"M Nakaichi","year":"1996","unstructured":"Nakaichi, M. et al. Establishment and characterization of a new canine B-cell leukemia cell line. J. Vet. Med. Sci. 58, 469\u2013471 (1996).","journal-title":"J. Vet. Med. Sci."},{"key":"68470_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0165-2427(97)00053-6","volume":"59","author":"Y Momoi","year":"1997","unstructured":"Momoi, Y. et al. Establishment and characterization of a canine T-lymphoblastoid cell line derived from malignant lymphoma. Vet. Immunol. Immunopathol. 59, 11\u201320 (1997).","journal-title":"Vet. Immunol. Immunopathol."},{"key":"68470_CR30","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1292\/jvms.12-0448","volume":"75","author":"S Umeki","year":"2013","unstructured":"Umeki, S. et al. Establishment of five canine lymphoma cell lines and tumor formation in a xenotransplantation model. J. Vet. Med. Sci. 75, 467\u2013474 (2013).","journal-title":"J. Vet. Med. Sci."},{"key":"68470_CR31","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1158\/1078-0432.CCR-04-1944","volume":"11","author":"SE Suter","year":"2005","unstructured":"Suter, S. E. et al. In vitro canine distemper virus infection of canine lymphoid cells: a prelude to oncolytic therapy for lymphoma. Clin. Cancer Res. 11, 1579\u20131587 (2005).","journal-title":"Clin. Cancer Res."},{"key":"68470_CR32","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.vetimm.2011.04.009","volume":"142","author":"S Umeki","year":"2011","unstructured":"Umeki, S. et al. Characterization of monoclonal antibodies against canine P-selectin glycoprotein ligand-1 (PSGL-1). Vet. Immunol. Immunopathol. 142, 119\u2013125 (2011).","journal-title":"Vet. Immunol. Immunopathol."},{"key":"68470_CR33","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.rvsc.2010.10.028","volume":"92","author":"T Okawa","year":"2012","unstructured":"Okawa, T. et al. Calreticulin expression in neoplastic versus normal dog mammary glands: a cDNA subtraction-based study. Res. Vet. Sci. 92, 80\u201391 (2012).","journal-title":"Res. Vet. Sci."},{"key":"68470_CR34","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1111\/jvim.12185","volume":"27","author":"L Thalheim","year":"2013","unstructured":"Thalheim, L., Williams, L. E., Borst, L. B., Fogle, J. E. & Suter, S. E. Lymphoma immunophenotype of dogs determined by immunohistochemistry, flow cytometry, and polymerase chain reaction for antigen receptor rearrangements. J. Vet. Intern. Med. 27, 1509\u20131516 (2013).","journal-title":"J. Vet. Intern. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68470-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68470-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68470-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T22:20:13Z","timestamp":1696371613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68470-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,10]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["68470"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-68470-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,10]]},"assertion":[{"value":"9 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.K. and T.M. have received research funding from Nippon Zenyaku Kogyo Co., Ltd. The rest of authors declare no other potential conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11476"}}